Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant High-Grade Neuroendocrine Tumor of the Lung
Yuyan Jiao, MM,
Ming Liu, MM,
Ningning Luo, MS,
Hao Guo, PhD,
Jianzhe Li, PhD
Affiliations
Yuyan Jiao, MM
Department of Oncology, Taian City Central Hospital, Taian, People’s Republic of China
Ming Liu, MM
Department of Oncology, Taian City Central Hospital, Taian, People’s Republic of China
Ningning Luo, MS
Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, People’s Republic of China
Hao Guo, PhD
Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, People’s Republic of China; State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing, People’s Republic of China
Jianzhe Li, PhD
Department of Oncology, Taian City Central Hospital, Taian, People’s Republic of China; Corresponding author. Address for correspondence: Jianzhe Li, PhD, Department of Oncology, Taian City Central Hospital, Taian, People’s Republic of China.
